title: Aberrant expression of extracellular signal-regulated kinase 5 in human prostate cancer.
abstract: Abnormal intracellular signaling contributes to carcinogenesis and may represent novel therapeutic targets. mitogen/extracellular signal-regulated kinase kinase-5 (MEK5) overexpression is associated with aggressive prostate cancer. In this study, we examined the role of extracellular signal-regulated kinase (ERK5, an MAPK and specific substrate for MEK5) in prostate cancer. ERK5 immunoreactivity was significantly upregulated in high-grade prostate cancer when compared to benign prostatic hyperplasia (P<0.0001). Increased ERK5 cytoplasmic signals correlated closely with Gleason sum score (P<0.0001), bony metastases (P=0.0044) and locally advanced disease at diagnosis (P=0.0023), with a weak association with shorter disease-specific survival (P=0.036). A subgroup of patients showed strong nuclear ERK5 localization, which correlated with poor disease-specific survival and, on multivariant analysis, was an independent prognostic factor (P<0.0001). Analysis of ERK5 expression in matched tumor pairs (before and after hormone relapse, n=26) revealed ERK5 nuclear expression was significantly associated with hormone-insensitive disease (P=0.0078). Similarly, ERK5 protein expression was increased in an androgen-independent LNCaP subline. We obtained the following in vitro and in vivo evidence to support the above expression data: (1) cotransfection of ERK5wt and MEK5D constructs in PC3 cells results in predominant ERK5 nuclear localization, similar to that observed in aggressive clinical disease; (2) ERK5-overexpressing PC3 cells have enhanced proliferative, migrative and invasive capabilities in vitro (P<0.0001), and were dramatically more efficient in forming tumors, with a shorter mean time for tumors to reach a critical volume of 1000 mm(3), in vivo (P<0.0001); (3) the MEK1 inhibitor, PD184352, blocking ERK1/2 activation at low dose, did not suppress proliferation but did significantly decrease proliferation at a higher dose required to inhibit ERK5 activation. Taken together, our results establish the potential importance of ERK5 in aggressive prostate cancer.
authors: Urology Research Group, Northern Institute for Cancer Research, University of Newcastle, Tyne and Wear, UK.
authors: S R C
authors: SR
authors: McCracken
authors: A
authors: A
authors: Ramsay
authors: R
authors: R
authors: Heer
authors: M E
authors: ME
authors: Mathers
authors: B L
authors: BL
authors: Jenkins
authors: J
authors: J
authors: Edwards
authors: C N
authors: CN
authors: Robson
authors: R
authors: R
authors: Marquez
authors: P
authors: P
authors: Cohen
authors: H Y
authors: HY
authors: Leung
mesh_terms: D000368:Aged; D000369:Aged, 80 and over; D049109:Cell Proliferation; D018572:Disease-Free Survival; D006801:Humans; D007150:Immunohistochemistry; D048671:MAP Kinase Kinase 5 / Q000235:genetics*; D008297:Male; D008875:Middle Aged; D011379:Prognosis; D011471:Prostatic Neoplasms / Q000201:enzymology* / Q000473:pathology
chemical_list: D048671:MAP Kinase Kinase 5; C482563:MAP2K5 protein, human